Graf Acquisition Corp. IV (NYSE:GFOR) announced in an 8-K this morning that it has added $10 million in convertible note funding to its combination with NKGen Biotech.
NKGen’s majority shareholder NKMax (KOSDAQ:182400) has put up the cash for the move and in exchange the notes are to bear interest payable at either a 5% rate in cash or 8% in stock. They will mature in 2027 on the agreement’s fourth anniversary and can be exercised for 1,000,000 shares at $11.50 per share.
This new funding comes as Graf IV has postponed its completion vote with NKGen three times as it engages with shareholders and tries to hit its $50 million minimum cash condition.
Its shareholders are currently set to reconvene at 10 am ET, September 20 and it has until September 25 to complete a deal.
Graf IV went into this string of meetings with about $62.2 million in trust and NKMax had already committed to a backstop of up to $25 million. According to the filing, the SPAC plans to continue to seek out additional funds to bring the deal to a close.
The $160 million combination was initially announced in April of this year. Santa Ana, California-based NKGen has five pharmaceutical formulas that have each reached some stage of Phase I and Phase II clinical trials seeking potential therapies for cancer and neurodegenerative conditions like Parkinson’s and Alzheimer’s.
Launch Two (NASDAQ:LPBBU) has filed for a $200 million IPO that shows how the market has shifted for new issuance since its sister SPAC Launch One (NASDAQ:LPAAU) filed just over a month ago. Both SPACs are underwritten by Cantor Fitzgerald and seeking nominally the same raise at IPO, but Launch Two is overfunding its trust...
FTAC Emerald (NASDAQ:EMLD) has entered into a definitive agreement to combine with crypto fintech firm Fold at an enterprise value of $381 million. Phoenix, Arizona-based Fold provides digital banking services backed by a treasury of Bitcoin that includes FDIC-secured checking accounts as well Bitcoin trading and awards. The combined company is expected to trade on...
At the SPAC of Dawn Dealmakers remain confident that AI is going to play a big role in their M&A processes, but feel unprepared for some the changes, according to a new survey of 225 corporate and 75 private equity transactions professionals. SS&C subsidiary Mergermarket generated the report that found more than half of respondents...
Trailblazer Merger I (NASDAQ:TBMC) has entered into a definitive agreement to combine with data intelligence firm Cyabra at an enterprise value of $70 million. Tel Aviv-based Cyabra provides tools to corporations and governments to identify fake accounts and combat social media disinformation. The combined company is expected to trade on the Nasdaq once the deal...
Chain Bridge I (NASDAQ:CBRG) has entered into a definitive agreement to combine with cannabinoid pharmaceuticals firm Phytanix Bio at a pre-deal valuation of $58 million. Santa Barbara, California-based Phytanix is working to develop bladder and seizure treatments using cannabis-based substances. The combined company is expected to trade on the Nasdaq under the symbol “PHYX” once...